Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma
- Conditions
- Neuroendocrine Carcinoma
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- Callisto Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT00663429
- Locations
- 🇺🇸
Hematology Oncology Services of Arkansas, Little Rock, Arkansas, United States
🇺🇸Mount Sinai Medical Center, New York, New York, United States
Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML
- Conditions
- Acute Lymphocytic LeukemiaAcute Myelogenous Leukemia
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- Callisto Pharmaceuticals
- Target Recruit Count
- 3
- Registration Number
- NCT00430443
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Denver Children's Hospital, Denver, Colorado, United States
🇺🇸Vanderbilt Children's Hospital, Nashville, Tennessee, United States
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
- Conditions
- Neuroendocrine Carcinoma
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Callisto Pharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT00388063
- Locations
- 🇺🇸
Hematology Oncology Services of Arkansas, Little Rock, Arkansas, United States
🇺🇸Cedars Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia
- Conditions
- Acute Lymphocytic Leukemia
- First Posted Date
- 2005-12-30
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Callisto Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT00271063
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer
- Conditions
- Advanced Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2006-12-05
- Lead Sponsor
- Callisto Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT00214838
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- Next